- Details
- Sam Chang hosts Silvia Proietti to discuss various laser technologies for upper urinary tract cancer (UTUC) treatment and their optimal applications. Dr. Proietti dives deep into the comparative use of Thulium YAG Laser, Holmium YAG laser, and TFL laser, emphasizing the importance of understanding laser-tissue interaction. She explores the role of pulse mode, depth of penetration, and the potentia...
|
- Details
- In a discussion led by Sam Chang, Surena Matin, and Craig Labbate present a study on nephroureterectomy's impact on renal function in patients with upper tract urothelial carcinoma. The retrospective review of 152 patients treated with neoadjuvant chemotherapy and nephroureterectomy over 20 years showed an average GFR decline of 22 milliliters per minute, stabilizing one to three months post-surge...
|
- Details
- Francesco Del Giudice and Ben Chung join Sam Chang in a discussion on addressing the contemporary trends of systemic neoadjuvant and adjuvant intravesical chemotherapy for upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy focused on a large insurance claim dataset from the United States. In this conversation, Francesco Del Giudice, and Ben Chung spe...
|
- Details
- Firas Petros, Urologic Oncologist from the University of Toledo College of Medicine joins Sam Chang in reviewing practice-changing and hypothesis-generating abstracts from the upper tract urothelial carcinoma podium session at the 2022 Annual Meeting of the American Urological Association (AUA). Dr. Petros first highlights two abstracts that involved the use of circulating tumor DNA as a biomarker...
|
- Details
- Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits join Sam Chang in a case-based discussion on approaches to the treatment of upper tract disease. The group evaluate a 75 years old, former smoker, who develops painless gross hematuria. His CT shows a 3-centimeter, left upper pole filling defect with a soft tissue mass. Labs are essentially normal. GFR is 65. The patient has good performance...
|
- Details
- Katie Murray joins Alicia Morgans to discuss reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC) via a percutaneous nephrostomy tube. Based on results from the pivotal OLYMPUS trial, JELMYTO® is currently approved for low-grade UTUC. Dr. Murray speaks to two different methods of administration of the mitomycin gel that was allowed in this trial...
|
- Details
- Wesley Yip joins Sam Chang in discussing variant histologies in the diagnosis of upper tract urothelial carcinoma. There are some unique challenges in managing upper tract urothelial carcinoma, and there still is a persistent need to define the impact of variant histology in the upper tract on patient outcomes to affect disease management, adjuvant therapies, and follow-up strategy. The purpose of...
|
- Details
- Nima Almassi joins Sam Chang to discuss some exciting abstract highlights about upper tract urothelial carcinoma presented at the AUA 2022. Dr. Almassi shares key takeaways on studies regarding nephron-sparing treatments for upper tract disease. He also discusses research on the increasing administration of intracavitary or topical treatment. The pair also discuss new developments in the field, in...
|
- Details
- Sam Chang interviews Sima Porten focusing on upper tract urothelial carcinoma. Dr. Porten emphasizes the crucial role of urologists as gatekeepers in disease management and the importance of adjuvant therapy for high-risk patients. She highlights the significant impact of adjuvant chemotherapy on event-free survival, citing the POUT data. The conversation explores the challenges of choosing betwee...
|
- Details
- In this discussion with Sam Chang, John Gore reviews an updated analysis of the OLYMPUS trial analyzing the durability or 12-month effectiveness of patients that had a complete response to MitoGel. The OLYMPUS trial evaluated the long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, (MitoGel) as primary chemoablative treatment for low-grade upper tract...
|
